首页> 外文期刊>Clinical & translational oncology : >Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy
【24h】

Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy

机译:一组专家对新辅助治疗后大肠癌肝转移肿瘤消退和非肿瘤肝组织损伤的病理学评估的建议

获取原文
获取原文并翻译 | 示例
           

摘要

Colorectal cancer (CRC) incidence has increased during the past decades in Spain, being the first malignant tumour in incidence. Observed mortality for CRC is mainly due to liver and lung metastases. The only curative treatment is surgery; new surgical techniques and neoadjuvant treatments have increased the number of surgery candidate patients. Patients should be managed with a multidisciplinary approach that includes imaging techniques, chemotherapy, surgery and pathological assessment. As an answer to this approach, a group of pathology experts interested on CRC liver metastases aimed to review the diagnosis and prognosis of liver mestastases and developed practical recommendations for its assessment. The expert group revised the current literature and prepared questions to be discussed based on available evidence and on their clinical practise. As a result, recommendations for the assessment of tumour regression of liver metastases are proposed, which could be implemented in oncology centres allowing assessment standardisation for these patients. Prospective multi-center studies to evaluate these recommendations validity will further contribute to improve the standard care of CRC liver metastases patients.
机译:在西班牙,结肠直肠癌(CRC)的发病率在过去几十年中有所增加,是发生率最高的恶性肿瘤。 CRC的死亡率主要归因于肝和肺转移。唯一的治疗方法是手术。新的手术技术和新辅助治疗增加了手术候选患者的数量。应该采用包括影像技术,化学疗法,手术和病理学评估在内的多学科方法来管理患者。作为对此方法的回答,一组对CRC肝转移感兴趣的病理学专家旨在审查肝转移的诊断和预后,并提出了评估的实用建议。专家组对现有文献进行了修订,并根据现有证据和临床实践准备了待讨论的问题。结果,提出了评估肝转移瘤消退的建议,可以在肿瘤学中心实施,以使这些患者的评估标准化。评估这些建议有效性的前瞻性多中心研究将进一步有助于改善CRC肝转移患者的标准治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号